Journal
CLINICAL INFECTIOUS DISEASES
Volume 74, Issue 9, Pages 1515-1524Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab687
Keywords
COVID-19; vaccine effectiveness; mRNA vaccines; hospitalized; immunocompromised
Categories
Funding
- US Centers for Disease Control and Prevention [75D30121F00002]
- Clinical and Translational Science Award from the National Center for Advancing Translational Sciences [UL1 TR002243]
- National Institute of Allergy And Infectious Diseases, National Institutes of Health [1K23AI137321]
- Centers for Disease Control and Prevention
Ask authors/readers for more resources
From March to May 2021, full vaccination using authorized mRNA products was associated with 87.1% protection against COVID-19 hospitalization among US adults, with lower effectiveness in adults with immunosuppression compared to those without. Vaccination was beneficial for patients with immunosuppression, but the effectiveness was lower in this population.
From March to May 2021, full vaccination using authorized mRNA products was associated with 87.1% (95% CI, 80.7-91.3) protection against COVID-19 hospitalization among US adults. Vaccine effectiveness was lower in adults with versus without immunosuppression (62.9% versus 91.3%). Background As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination coverage increases in the United States, there is a need to understand the real-world effectiveness against severe coronavirus disease 2019 (COVID-19) and among people at increased risk for poor outcomes. Methods In a multicenter case-control analysis of US adults hospitalized March 11-May 5, 2021, we evaluated vaccine effectiveness to prevent COVID-19 hospitalizations by comparing odds of prior vaccination with a messenger RNA (mRNA) vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with COVID-19 and hospital-based controls who tested negative for SARS-CoV-2. Results Among 1212 participants, including 593 cases and 619 controls, median age was 58 years, 22.8% were Black, 13.9% were Hispanic, and 21.0% had immunosuppression. SARS-CoV-2 lineage B0.1.1.7 (Alpha) was the most common variant (67.9% of viruses with lineage determined). Full vaccination (receipt of 2 vaccine doses >= 14 days before illness onset) had been received by 8.2% of cases and 36.4% of controls. Overall vaccine effectiveness was 87.1% (95% confidence interval [CI], 80.7-91.3). Vaccine effectiveness was similar for Pfizer-BioNTech and Moderna vaccines, and highest in adults aged 18-49 years (97.4%; 95% CI, 79.3-9.7). Among 45 patients with vaccine-breakthrough COVID hospitalizations, 44 (97.8%) were >= 50 years old and 20 (44.4%) had immunosuppression. Vaccine effectiveness was lower among patients with immunosuppression (62.9%; 95% CI,20.8-82.6) than without immunosuppression (91.3%; 95% CI, 85.6-94.8). Conclusion During March-May 2021, SARS-CoV-2 mRNA vaccines were highly effective for preventing COVID-19 hospitalizations among US adults. SARS-CoV-2 vaccination was beneficial for patients with immunosuppression, but effectiveness was lower in the immunosuppressed population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available